Lixte Biotechnology Holdings Inc (XETR:8640) Share Price

Company Profile

Business description
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Contact
680 East Colorado Boulevard
Suite 180
PasadenaCA91101
USA
T: +1 631 830-7092
https://www.lixte.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
4

Recommended

Our best resources to help investors determine the value of a share.

Morningstar | 24 August 2025

Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.

Joseph Taylor | 24 August 2025

Although Guzman y Gomez had solid earnings, it failed to meet lofty market expectations.

Johannes Faul, CFA | 24 August 2025

Index	Last price	Change	% Change
All Ordinaries	9,268.80	42.50	-0.46%
CAC 40	7,969.69	31.40	0.40%
DAX 40	24,363.09	69.75	0.29%
Dow JONES (US)	45,631.74	846.24	1.89%
FTSE 100	9,321.40	12.20	0.13%
HKSE	25,866.49	527.35	2.08%
NASDAQ	21,496.54	396.22	1.88%
Nikkei 225	42,756.94	123.65	0.29%
NZX 50 Index	13,082.80	40.04	0.31%
S&P 500	6,466.91	96.74	1.52%
S&P/ASX 200	8,998.00	46.10	-0.51%
SSE Composite Index	3,858.59	32.83	0.86%